The TRIUMPH-4 retatrutide Phase 3 trial (NCT05996731) addresses obesity-with-comorbidity populations within Eli Lilly's broader TRIUMPH program (TRIUMPH-1 through TRIUMPH-5). The headline result consistent across the published TRIUMPH readouts: ~24% mean body-weight reduction at 48 weeks at the 12 mg top dose — 2–4 percentage points above tirzepatide's SURMOUNT ceiling. Eli Lilly's 2026 FDA submission target implies a possible approval decision window of late 2026 to mid-2027.
What we read
The published TRIUMPH Phase 3 program readouts (TRIUMPH-1 through TRIUMPH-5) as available in NEJM, JAMA, and Lancet through April 2026; the corresponding ClinicalTrials.gov NCT entries (NCT05882045, NCT05952713, NCT05882187, NCT05996731, and the TRIUMPH-5 record); Eli Lilly's quarterly earnings calls and investor presentations referencing the retatrutide program from 2025–2026; and the FDA advisory-committee briefing documents posted publicly to date. This is a literature read, not a clinical-practice synthesis or a buyer's guide.
The TRIUMPH program at a glance
The TRIUMPH Phase 3 program reads out across five trials covering different patient populations and endpoints. Here is the roster:
| Trial | NCT ID | Population | Primary endpoint | Status (May 2026) |
|---|---|---|---|---|
| TRIUMPH-1 | NCT05882045 | Obesity / overweight | Weight loss at 48 weeks | Published |
| TRIUMPH-2 | NCT05952713 | Obesity + type 2 diabetes | Weight loss + HbA1c | Published |
| TRIUMPH-3 | NCT05882187 | Knee osteoarthritis + obesity | Weight loss + WOMAC pain | Published |
| TRIUMPH-4 | NCT05996731 | Obesity + comorbidities (CV-risk enriched) | Weight loss in CV-risk population | Published |
| TRIUMPH-5 | (record live) | Cardiovascular outcomes (MACE) | Major adverse cardiovascular events vs placebo | Enrolling — primary endpoint not yet published |
Why TRIUMPH-4 matters: the comorbidity bridge
TRIUMPH-4 is the readout that addresses obesity-with-comorbidity populations — the dimension on which retatrutide differentiates clinically from tirzepatide. The Phase 2 retatrutide data (Jastreboff et al., NEJM 2023) showed weight-loss magnitude superior to tirzepatide. The Phase 3 question was whether that magnitude advantage holds at scale, in patients with metabolic comorbidities, and across longer treatment duration.
TRIUMPH-1 through TRIUMPH-3 addressed weight-loss-only populations across different baseline characteristics. TRIUMPH-4 adds the comorbidity dimension. TRIUMPH-5 addresses the cardiovascular-outcomes endpoint specifically — the bar that GLP-1-class drugs are increasingly held to following the SELECT trial precedent for semaglutide.
What TRIUMPH-4 results showed: 24% mean weight loss at 48 weeks
The headline Phase 3 retatrutide weight-loss figure consistent across the published TRIUMPH readouts: ~24% mean body-weight reduction at the highest tested dose at 48 weeks, holding from the Phase 2 ceiling. This is approximately 2–4 percentage points above the highest-dose tirzepatide ceiling in the SURMOUNT trials.
| Compound | Mechanism | Peak weight loss (Phase 3, 48-week, top dose) |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 mono-agonist | ~15% |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual-agonist | ~21% |
| Retatrutide | GLP-1 + GIP + glucagon triple-agonist | ~24% |
Headline Phase 3 weight-loss figures at the highest-tested dose, 48 weeks. Retatrutide TRIUMPH ceiling (~24%) tops the tirzepatide SURMOUNT ceiling (~21%) by 2–4 percentage points; the trajectory continues past 48 weeks in retatrutide open-label-extension data.
Three structural observations on the readout:
The curve does not plateau as early. The retatrutide weight-loss trajectory in the TRIUMPH trials continues sloping down past the 48-week mark in the open-label-extension data. Tirzepatide and semaglutide show flatter slopes by the 40-week mark in their respective Phase 3 readouts. The mechanism explanation is the third receptor (glucagon), which contributes to energy expenditure rather than just appetite suppression.
The side-effect profile is class-similar, with one specific addition. GI side effects (nausea, vomiting, dose-titration tolerability) are broadly comparable to the GLP-1 mono- and dual-agonists. The glucagon-receptor activity introduces a heart-rate elevation signal that is being monitored carefully in the TRIUMPH-4 and TRIUMPH-5 readouts — modest in magnitude (1–3 bpm above baseline across reported populations) but distinct from the other GLP-1-class compounds.
Tolerability scales with titration discipline. The trial protocols use slower dose-titration schedules than were typical in earlier GLP-1 Phase 3 programs. Discontinuation rates due to adverse events in the published Phase 3 readouts are in line with tirzepatide SURMOUNT figures, which is meaningful given the larger weight-loss effect.
What the TRIUMPH readouts have not yet answered
Three categories of question that the trial readouts have not answered as of April 2026.
Long-term durability beyond 88 weeks. The longest published TRIUMPH readout extends to 88 weeks. Whether the weight-loss trajectory continues past 100+ weeks, or whether it plateaus as the glucagon-receptor adaptation catches up to the mechanism, is not yet in the public record.
Cardiovascular outcomes superiority. TRIUMPH-5 is the trial that addresses this directly, and as of April 2026 the headline endpoint data is not yet published. The interim safety readouts have been acceptable; the efficacy readout against placebo for major adverse cardiovascular events is the bar GLP-1-class drugs face for a label that supports cardio-protective indications.
Special populations. Pediatric, hepatic-impairment, and pregnant populations are not covered by the published TRIUMPH program. These are typical post-approval study commitments, not Phase 3 program exclusions.
What changes if Eli Lilly's 2026 FDA retatrutide submission proceeds
The Eli Lilly investor communications through Q1 2026 indicated a 2026 FDA submission target for retatrutide. As of this writing (May 2026), the submission timing is current-quarter or near-quarter. Two paths from here:
Path A — submission and standard review (12-month timeline). A mid-2026 submission with standard review puts a possible approval decision in mid-2027. The label would likely follow the tirzepatide pattern (chronic weight management in adults with obesity or overweight with weight-related comorbidities). Tirzepatide's Wegovy and Zepbound branding precedent suggests the brand version of retatrutide enters market in 2027.
Path B — submission and priority review (6-month timeline). Less likely given the size of the trial program but possible if the TRIUMPH-5 cardiovascular readout is sufficiently favorable. This path shifts the approval-decision window into late 2026 or early 2027.
The buyer-side implications are bounded. For research-peptide buyers, the regulatory state in May 2026 remains: retatrutide is not FDA-approved, no compounded version is legally available (retatrutide is not on the 503A compounding pathway and not in a brand-product shortage exemption), and any retatrutide obtained for human use is unsupervised. The cleanest legal route remains participation in the TRIUMPH-5 trial or successor trials where they remain enrolling.
For the legal compounded-GLP-1 market, the TRIUMPH program data is indirect news. The April 2026 PCAC reaffirmation (see our enforcement timeline) maintains the compounding restrictions on the GLP-1 class. A brand-approved retatrutide in 2027 does not change that picture; it adds a brand product to the legal-prescription channel without opening the compounding channel.
What we don't address
This article is a literature read on the trial program. It is deliberately not a buyer's guide to research-peptide retatrutide. We do not link to or recommend any research-peptide vendor for this compound, regardless of audit tier. The reasoning:
- Retatrutide is in active Phase 3 with no FDA approval. Marketing language that frames research-peptide retatrutide as an alternative to clinical retatrutide is the type of language that has driven multiple FDA Warning Letters in the 2024–2026 period.
- The Janoshik COA data we documented in the Peptide Sciences postmortem shows the retatrutide research-peptide market specifically had high purity variance through the 2025–2026 cycle. The lab data does not support a confident vendor recommendation for this compound.
- Vialaudit's audit-tier policy treats unapproved-drug compounds with active Phase 3 programs as a separate category from research-only research peptides. The full audit cycle does not extend to retatrutide vendor recommendations until the regulatory state moves forward.
Sources
- TRIUMPH program: ClinicalTrials.gov NCT05882045 (TRIUMPH-1), NCT05952713 (TRIUMPH-2), NCT05882187 (TRIUMPH-3), NCT05996731 (TRIUMPH-4)
- Phase 2 retatrutide: Jastreboff et al., NEJM 2023
- Tirzepatide SURMOUNT comparator: SURMOUNT-1 publication
- Eli Lilly investor relations: quarterly earnings calls 2025–2026, retatrutide program updates
- FDA briefing documents (advisory committees)
- Internal: FDA peptide enforcement, 2024–2026, Janoshik 7,164-tests purity analysis, Retatrutide vs Tirzepatide research comparison
Frequently asked
What did the TRIUMPH-4 trial show?
TRIUMPH-4 is the Phase 3 retatrutide readout that addresses obesity-with-comorbidity populations — the dimension on which retatrutide differentiates clinically from tirzepatide. The published TRIUMPH program shows ~24% mean body-weight reduction at the 12 mg top dose at 48 weeks, with the weight-loss trajectory continuing past the 48-week mark in open-label-extension data. The side-effect profile is class-similar to GLP-1 mono- and dual-agonists, with one distinct addition: a 1–3 bpm heart-rate elevation attributable to glucagon-receptor activity.
When will retatrutide be FDA approved?
Eli Lilly's investor communications through Q1 2026 indicated a 2026 FDA submission target. With standard 12-month review, an approval decision could land in mid-2027. Priority review (less likely given trial-program size) could shift that into late 2026 or early 2027. The brand-product launch timing is contingent on labeling and post-marketing commitments after the approval decision.
Is retatrutide better than tirzepatide?
On the headline Phase 3 weight-loss endpoint, yes — ~24% mean body-weight reduction for retatrutide at the 12 mg dose versus ~21% for tirzepatide at the 15 mg dose in SURMOUNT. The retatrutide curve also slopes down longer before plateauing. Tradeoffs are the 1–3 bpm heart-rate signal from glucagon-receptor activity (which tirzepatide doesn't have) and the still-unpublished TRIUMPH-5 cardiovascular outcomes readout — the bar that GLP-1-class drugs now face.
What doses are used in the TRIUMPH Phase 3 trials?
The TRIUMPH Phase 3 program tests retatrutide across four maintenance doses — 1 mg, 4 mg, 8 mg, and 12 mg, administered weekly via subcutaneous injection. The 24% mean weight-loss headline comes from the 12 mg arm. The published titration approach is slower than tirzepatide SURMOUNT — initiation at 2 mg, step-ups every ~4 weeks to maintenance — specifically to manage the heart-rate signal and GI tolerability. Full dosing-protocol detail at /articles/retatrutide-dosing-protocols.
Has retatrutide been published in NEJM or Lancet?
The Phase 2 retatrutide results were published in NEJM (Jastreboff et al., 2023) showing the weight-loss ceiling that the Phase 3 TRIUMPH program subsequently confirmed at scale. Phase 3 TRIUMPH-1 through TRIUMPH-4 readouts have appeared across NEJM, JAMA, and Lancet through April 2026. TRIUMPH-5 (the cardiovascular outcomes trial) has not yet released its primary endpoint as of May 2026.